CervoMed (CRVO) announced key takeaways from two oral presentations characterizing the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies, DLB, that were presented at ...
Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results